Identification of a Novel Positron Emission Tomography (PET) Ligand for Imaging β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE-1) in Brain-Reference-Cited by-同舟云学术

Identification of a Novel Positron Emission Tomography (PET) Ligand for Imaging β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE-1) in Brain

Published:2018-01-22 Issue:8 Volume:61 Page:3296-3308
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Zhang Lei¹^ORCID,Chen Laigao²,Dutra Jason K.³,Beck Elizabeth M.¹,Nag Sangram⁴,Takano Akihiro⁴,Amini Nahid⁴,Arakawa Ryosuke⁴,Brodney Michael A.¹,Buzon Leanne M.³,Doran Shawn D.⁵,Lanyon Lorraine F.⁵,McCarthy Timothy J.²,Bales Kelly R.⁶,Nolan Charles E.⁶,O’Neill Brian T.³^ORCID,Schildknegt Klaas⁷,Halldin Christer⁴,Villalobos Anabella⁸

Affiliation:

1. Medicine Design, Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts 02139, United States

2. Clinical & Translational Imaging, Early Clinical Development, Pfizer Inc., Cambridge, Massachusetts 02139, United States

3. Medicine Design, Medicinal Chemistry, Pfizer Inc., Groton, Connecticut 06340, United States

4. Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-17176 Stockholm, Sweden

5. Medicine Design, Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, Connecticut 06340, United States

6. Internal Medicine, Pfizer Inc., Cambridge, Massachusetts 02139, United States

7. Pharmaceutical Sciences, Pfizer Inc., Groton, Connecticut 06340, United States

8. Medicinal Synthesis Technologies, Pfizer Inc., Groton, Connecticut 06340, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b01769

Reference39 articles.

1. 2012 Alzheimer’s Disease facts and figures; Alzheimer’s Association: Washington DC, 2012; https://www.alz.org/downloads/facts_figures_2012.pdf.

2. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

3. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

4. PET imaging of amyloid in Alzheimer's disease

5. Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging targets for positron emission tomography imaging in proteinopathies;npj Imaging;2024-08-21

2. Preclinical Evaluation of Novel Positron Emission Tomography (PET) Probes for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2);Journal of Medicinal Chemistry;2024-02-02

3. RO6807936 as a novel positron emission tomography (PET) radiotracer for in vitro and in vivo visualization and quantification of beta‐site amyloid precursor protein cleaving enzyme (BACE1) in the rodent and baboon brain;Journal of Labelled Compounds and Radiopharmaceuticals;2023-05-11

4. Etiology of Alzheimer's Disease;Discovery Medicine;2023

5. Imaging Leucine-Rich Repeat Kinase 2 In Vivo with ¹⁸F-Labeled Positron Emission Tomography Ligand;Journal of Medicinal Chemistry;2022-10-18